INO20250516P8
INO May 16 2025 8.00 Put (INO250516P00008000)
option OPRA

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.